Abstracts at 42.18% compared to 25.91% of LLD (p < 0.0001). Bleeding, readmission, and mortality were similar (p = NS). Risk-adjusted logistic regression also found no evidence for better outcome in patients given HLD of clopidogrel. CONCLUSIONS: Using time-stamp data, this large study retrospectively investigated effects of HLD clopidogrel in usual care setting. Patients receiving HLD did not experience better outcome. If providers tend to select HLD to treat high-risk patients in practice, an underlying dose-outcome bias would exist in the data. It is unclear how much of the bias is mitigated by higher dosing in the usual care setting. More research is needed. To review the existing evidence of the economic impact of contrast echocardiography (CE) in the diagnosis and management of patients with suspected or known coronary artery disease (CAD). METHODS: A systematic search was undertaken to identify studies that provided empirical evidence of the cost-effectiveness of CE relative to an alternative diagnostic modality. Findings and study methodologies were reviewed and suggestions for further research were offered. RESULTS: Six studies were identified, including one conference abstract and one unpublished study. In four studies of patients with sub-optimal un-enhanced echocardiogaphic images, CE was reported to reduce the average cost to obtain a diagnosis by 17-64% compared with a second-line nuclear imaging (SPECT) test. However, these studies did not include the impact of potential differences in diagnostic accuracy between tests. A fifth study reported that compared with trans-oesophageal echocardiography CE resulted in similar yield of accurate diagnoses at a substantial reduction in costs for determination of regional and global ventricular function in 'technically difficult to image' patients. In a sixth study in patients with an intermediate risk for CAD, the average cost to identify CAD was lowest when SPECT Tc-99m or CE ($267 and $355 per case detected, respectively) and highest when exercise electrocardiography ($1320 per case detected) was used as the first-line test.
PCV32 LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND

Pietrasik
OBJECTIVES:
The efficacy of platelet inhibition with clopidogrel for patients (pts) with non-ST-elevation acute coronary syndromes was demonstrated in CURE and PCI-CURE trials. The purpose of present analysis is to estimate the long-term costeffectiveness of clopidogrel in Poland, using clinical outcomes and resource utilization from CURE and in PCI-CURE. METHODS: Costs of hospitalizations and studied drugs were calculated based on resource utilization collected in case report form for all pts in CURE (clopidogrel, n = 6259, placebo, n = 6303) and in the subgroup of PCI-CURE pts (clopidogrel/n = 1313, placebo/n = 1345). Comedications were not included in the economic analyses as drug utilization was similar in clopidogrel and placebo group. Unit costs were calculated using drugs retail prices and medical procedures tariffs contracted by National Health Found. Because of lack of sufficient Polish epidemiological data two different sources (Framingham and Saskatchewan databases) were used to evaluate the lost life expectancy associated with death, MI and stroke. A discount rate of 3% was applied. Results are expressed in cost per Life Year Saved. RESULTS: Total cost per pt was higher in the clopidogrel arm for CURE and PCI-CURE (+€463 and +€454) respectively. The estimated number of LYS with clopidogrel for CURE pts was 69.9 per 1000 pts treated using (CVD) . In primary prevention the use of Aspirin is not fully established although meta-analyses and guidelines support its use in persons at increased CVD risk. This study assessed the health economic consequences of the use of low-dose Aspirin in the primary prevention of CVD in the UK, Germany, Spain and Italy. METHODS: Based on results reported in two meta-analyses, a Markov model was developed to predict the cost-effectiveness of Aspirin in the primary prevention of CVD. Different time horizons (1 to 10 years), 1-year cycles and direct costs from the health care payer's perspective (2003) were used. Effects were expressed in Life-Years (LY) and QALY. Utility data (TTO) were obtained from published data. Country specific discounting was applied. RESULTS: For patients with an annual risk of coronary heart disease (CHD) of 1.5%, the model results in average savings with low-dose aspirin after 10 years of €201 €122-731] per patient in the UK, Germany, Spain and Italy, respectively. Although the savings in the first year are modest (on average €10-€20), from the second year on they are significant in all countries. Sensitivity analysis showed the results robustness. The number of LY and QALY gained with aspirin were respectively 0.2 and 0.4 years in the four countries. Monte Carlo analysis showed aspirin-dominance in ± 97% of cases for the three studied annual risks of CHD (0.6%, 1.0% and 1.5%) except for Italy, where dominance in ≥95% was seen at annual risks of 1% and 1.5%. CON-CLUSIONS: Administering low-dose Aspirin to patients with an annual risk of CHD of ≥1% is significantly cost-saving from the health care payer's perspective in all countries analysed. Savings start after one year of treatment.
PCV34
Nationale des Coûts": National Study of Costs) database of public sector. The PMSI ("Programme de Médicalisation des Systèmes d'Information") is the French equivalent of DRG system. The GHM ("Groupes Homogènes de Malades": Homogeneous Groups of Patients) corresponding to cardiovascular events were determined from classifying medical procedure (CdAM: "Classification Des Actes Médicaux") and/or from main diagnosis (ICD 10: International Classification of Diseases). The numbers of hospitalizations were then determined. The most representative GHM were selected, and associated prices/costs have been weighted by suitable numbers of hospitalizations in order to obtain an average price/cost of hospitalization. RESULTS: Average prices (private sector) and costs (public sector) have been estimated respectively in private and public sector at €1815 and €1315 for a coronarography, €2704 and €2971 for a coronary angioplasty (€5750 and €5178 with stenting), €14,905 and €13,119 for an aorto-coronary bypass, €4271 and €4216 for a myocardial infarction (including procedures), €2967 and €3483 for a cerebrovascular accident, €1799 et €2570 for a transient ischemic attack, €1589 and €2350 for stable and unstable angina, €2433 et €3658 for a heart failure. CONCLUSION: It is difficult to isolate specific hospital prices/costs of cardiovascular events. Nevertheless those approximations seem to be the only way to assess these prices/costs, which in addition are likely to be used in pharmacoeconomic models.
